Heron Therapeutics Inc. (NASDAQ: HRTX) is -13.06% lower on its value in year-to-date trading and has touched a low of $12.52 and a high of $22.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The HRTX stock was last observed hovering at around $17.95 in the last trading session, with the day’s gains setting it 0.45% off its average median price target of $28.00 for the next 12 months. It is also 73.71% off the consensus price target high of $70.00 offered by 8 analysts, but current levels are 26.4% higher than the price target low of $25.00 for the same period.
Currently trading at $18.40, the stock is 7.29% and 7.72% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.77 million and changing 2.51% at the moment leaves the stock 8.19% off its SMA200. HRTX registered 23.49% gain for a year compared to 6-month loss of 11.72%. The firm has a 50-day simple moving average (SMA 50) of $16.95 and a 200-day simple moving average (SMA200) of $17.42.
The stock witnessed a 22.10% gain in the last 1 month and extending the period to 3 months gives it a 3.49%, and is 1.32% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.03% over the week and 4.66% over the month.
Heron Therapeutics Inc. (HRTX) has around 223 employees, a market worth around $1.76B and $88.60M in sales. Distance from 52-week low is 46.96% and -17.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-93.70%).
Heron Therapeutics Inc. (HRTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Heron Therapeutics Inc. (HRTX) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Heron Therapeutics Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.58 with sales reaching $25.85M over the same period.The EPS is expected to shrink by 0.00% this year, but quarterly earnings will post 75.60% year-over-year. Quarterly sales are estimated to grow 1.80% in year-over-year returns.
Heron Therapeutics Inc. (HRTX) Top Institutional Holders
274 institutions hold shares in Heron Therapeutics Inc. (HRTX), with 137.09k shares held by insiders accounting for 0.15% while institutional investors hold 100.86% of the company’s shares. The shares outstanding are 91.08M, and float is at 90.59M with Short Float at 23.63%. Institutions hold 100.71% of the Float.
The top institutional shareholder in the company is Franklin Resources, Inc. with over 12.69 million shares valued at $268.56 million. The investor’s holdings represent 13.84% of the HRTX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 8.31 million shares valued at $175.92 million to account for 9.07% of the shares outstanding. The other top investors are Wellington Management Group, LLP which holds 6.94 million shares representing 7.57% and valued at over $146.8 million, while Blackrock Inc. holds 7.51% of the shares totaling 6.89 million with a market value of $145.76 million.
Heron Therapeutics Inc. (HRTX) Insider Activity
A total of 28 insider transactions have happened at Heron Therapeutics Inc. (HRTX) in the last six months, with sales accounting for 14 and purchases happening 14 times. The most recent transaction is an insider sale by Christian Waage, the company’s Director. SEC filings show that Christian Waage sold 300 shares of the company’s common stock on Apr 15 at a price of $17.51 per share for a total of $5254.0. Following the sale, the insider now owns 4100.0 shares.
Heron Therapeutics Inc. disclosed in a document filed with the SEC on Apr 06 that Johnson Craig A (Director) sold a total of 250 shares of the company’s common stock. The trade occurred on Apr 06 and was made at $17.22 per share for $4305.0. Following the transaction, the insider now directly holds 3590.0 shares of the HRTX stock.
Still, SEC filings show that on Jan 14, Szekeres David Leslie (EVP, Chief Operating Officer) disposed off 827 shares at an average price of $18.09 for $14960.0. The insider now directly holds 0 shares of Heron Therapeutics Inc. (HRTX).
Heron Therapeutics Inc. (HRTX): Who are the competitors?
The company’s main competitors (and peers) include Ligand Pharmaceuticals Incorporated (LGND) that is trading 57.43% up over the past 12 months. Surmodics Inc. (SRDX) is 60.38% up on the 1-year trading charts. Short interest in the company’s stock has fallen -4.18% from the last report on Apr 14, 2021 to stand at a total of 21.41 million short shares sold with a short interest ratio of 18.85.